Vir Biotechnology (VIR) pipeline and stated timing

Name in SEC filings: Vir Biotechnology, Inc.

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
VIR-5818	/data readout	Phase 1	second half of 2026	8-K · Aug 5, 2026
elebsiran + tobevibart	Topline/data readout	Phase 3	fourth quarter of 2026	8-K · Aug 5, 2026

Source: ORION, orionbiotechai.com/company/VIR, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/VIR

Nearest upcoming stated timing: VIR-5818 · Topline/data readout · second half of 2026

SEC sources last checked Oct 13, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

VIR-5818

Matched

Topline/data readoutsecond half of 2026

Stage: Phase 1SEC filing · “Phase 1”

Public float: $689,200,000 · as of Jun 30, 2025 · SEC filing

The Company expects to report updated dose-escalation data from its Phase 1 trial evaluating VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, as a monotherapy and in combination with pembrolizumab, in the second half of 2026.

8-K · Filed Aug 5, 2026 · Last checked Oct 13, 2026

Source details

Accession 0001628280-26-053351

Alert me · Calendar: same stage and window-end month (2026-12)

elebsiran + tobevibart

Matched

Topline/data readoutfourth quarter of 2026

Stage: Phase 3SEC filing · “Phase 3”

Public float: $689,200,000 · as of Jun 30, 2025 · SEC filing

Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.

8-K · Filed Aug 5, 2026 · Last checked Oct 13, 2026

Source details

Accession 0001628280-26-053351

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event	Stated period and SEC wording	Disclosure in stated period
elebsiran + tobevibartClinical results	fourth quarter of 2026 “Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.” Filed Aug 5, 2026 · EX-99.1	Still within period As of Oct 19, 2026
VIR-5818Clinical results	second half of 2026 “The Company expects to report updated dose-escalation data from its Phase 1 trial evaluating VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, as a monotherapy and in combination with pembrolizumab, in the second half of 2026.” Filed Aug 5, 2026 · EX-99.1	Still within period As of Oct 19, 2026
elebsiran + tobevibartClinical results	fourth quarter of 2026 “• Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.” Filed May 7, 2026 · 10-Q	Still within period As of Oct 19, 2026
VIR-5818Clinical results	second half of 2026 “VIR-5818 • Phase 1 dose-escalation of VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, in combination with pembrolizumab continues, with response data expected in the second half of 2026.” Filed May 7, 2026 · 10-Q	Still within period As of Oct 19, 2026
elebsiran + tobevibartClinical results	fourth quarter of 2026 “• Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.” Filed May 6, 2026 · EX-99.1	Still within period As of Oct 19, 2026
VIR-5818Clinical results	second half of 2026 “VIR-5818 • Phase 1 dose-escalation of VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, in combination with pembrolizumab continues, with response data expected in the second half of 2026.” Filed May 6, 2026 · EX-99.1	Still within period As of Oct 19, 2026
elebsiran + tobevibartClinical results	fourth quarter of 2026 “Topline results from ECLIPSE 1 are expected in the fourth quarter of 2026” Filed Feb 23, 2026 · 10-K	Still within period As of Oct 19, 2026
elebsiran + tobevibartClinical results	fourth quarter of 2026 “Topline data from the ECLIPSE 1 trial are expected in the fourth quarter of 2026.” Filed Feb 23, 2026 · 10-K	Still within period As of Oct 19, 2026
VIR-5818Clinical results	second half of 2026 “VIR-5818 • Phase 1 dose-escalation of VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, in combination with pembrolizumab continues, with response data expected in the second half of 2026.” Filed Feb 23, 2026 · 10-K	Still within period As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch VIR

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for VIR. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See VIR in the calendar · Review labels and methodology